Repro Med Systems, dba RMS Medical Products has received 510(k) clearance from the US Food and Drug Administration (FDA) for its HIgh-Flo Super26 subcutaneous needle sets (Super 26 Needle Sets).

MDPR1

Image: RMS Medical Products receives FDA 510(k) clearance for HIgh-Flo Super26 needles. Photo: Courtesy of truengtra_pae/FreeDigitalPhotos.net

The Super26 Needle Sets are indicated for subcutaneous infusion of medications in the home, hospital, or ambulatory settings to facilitate high flow rates, including human plasma-derived immunoglobulins such as Hizentra and Cuvitru.

Expanding on RMS Medical’s well-regarded lineup of HIgH-Flo needle sets, the Super26 Needle Sets utilize a proprietary design to provide 26-gauge comfort with significantly faster flow rates. The Super26 Needle Sets will be offered as a single-needle set, as well as 2-needle, 3-needle, 4- needle, 5-needle, 6-needle sets; through use of a Y-connector, 7-needle and 8-needle sets may also be assembled. The sets will be available as part of RMS Medical’s Freedom Integrated Infusion System, the only fully-integrated mechanical system cleared by the FDA for a wide range of medications and flow rates.

“This clearance reflects our commitment to broadening RMS Medical’s product portfolio with solutions that optimize the delivery and efficacy of subcutaneous therapies, promote compliance, and improve the overall patient experience,” said Don Pettigrew, President and Chief Executive Officer. “The Super26 Needle Sets support the shift towards faster SCIg infusions while addressing patient comfort concerns via the use of a smaller diameter needle. This could be very helpful in existing and new indications where large volumes of drugs are required to be infused.”

“RMS Medical continues to define itself as an industry leader,” said Daniel Goldberger, Executive Chairman. “New product introduction is an important component of our previously announced strategic plan. As we advance towards our vision of becoming the preferred drug delivery partner for specific infusion therapies in select markets, we will continue to focus on delivering innovative solutions to our growing industry.”

Source: Company Press Release